These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 27291066)

  • 41. Turoctocog alfa for the treatment of hemophilia a.
    Vakil NH; Fujinami N; Martin-Stone S
    Pharmacotherapy; 2014 Oct; 34(10):1091-101. PubMed ID: 25052207
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Prevention of hemorrhage in patients with hemophilia].
    Pliushch OP; Rutberg RA; Zakhrova NS; Shefter LI
    Probl Gematol Pereliv Krovi; 1976 Jan; 21(1):11-3. PubMed ID: 1273055
    [No Abstract]   [Full Text] [Related]  

  • 43. Eloctate for hemophilia A.
    Med Lett Drugs Ther; 2015 Oct; 57(1479):143-4. PubMed ID: 26445206
    [TBL] [Abstract][Full Text] [Related]  

  • 44. How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access.
    Nijdam A; Kurnik K; Liesner R; Ljung R; Nolan B; Petrini P; Fischer K;
    Haemophilia; 2015 Jul; 21(4):444-50. PubMed ID: 25582494
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prophylaxis in haemophilic children.
    Liesner RJ
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S7-10. PubMed ID: 9351529
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prophylaxis re-visited: The potential impact of novel factor and non-factor therapies on prophylaxis.
    Carcao M; Lambert T; Leissinger C; Escuriola-Ettingshausen C; Santagostino E; Aledort L;
    Haemophilia; 2018 Nov; 24(6):845-848. PubMed ID: 29989273
    [No Abstract]   [Full Text] [Related]  

  • 47. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs.
    Tagliaferri A; Franchini M; Coppola A; Rivolta GF; Santoro C; Rossetti G; Feola G; Zanon E; Dragani A; Iannaccaro P; Radossi P; Mannucci PM
    Haemophilia; 2008 Sep; 14(5):945-51. PubMed ID: 18540895
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.
    Valentino LA; Pipe SW; Collins PW; Blanchette VS; Berntorp E; Fischer K; Ewenstein BM; Oh M; Spotts G
    Haemophilia; 2016 Jul; 22(4):514-20. PubMed ID: 26930418
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A.
    Takedani H; Hirose J
    Drug Des Devel Ther; 2015; 9():1767-72. PubMed ID: 25848213
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of low-dose prophylaxis of highly purified plasma-derived factor VIII concentrate produced by the National Blood Centre, Thai Red Cross Society.
    Chuansumrit A; Sosothikul D; Natesirinilkul R; Lektrakul Y; Charoonruangrit U;
    Haemophilia; 2018 Sep; 24(5):e387-e390. PubMed ID: 30117632
    [No Abstract]   [Full Text] [Related]  

  • 51. Physician preferences for medication attributes for the prophylactic treatment of patients with severe haemophilia A with inhibitors to factor VIII.
    Gelhorn H; Merikle E; Krishnan S; Nemes L; Leissinger C; Valentino L
    Haemophilia; 2013 Jan; 19(1):119-25. PubMed ID: 23005041
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors.
    Leissinger C; Gringeri A; Antmen B; Berntorp E; Biasoli C; Carpenter S; Cortesi P; Jo H; Kavakli K; Lassila R; Morfini M; Négrier C; Rocino A; Schramm W; Serban M; Uscatescu MV; Windyga J; Zülfikar B; Mantovani L
    N Engl J Med; 2011 Nov; 365(18):1684-92. PubMed ID: 22047559
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term prophylaxis in severe haemophilia seems to preserve bone mineral density.
    Khawaji M; Akesson K; Berntorp E
    Haemophilia; 2009 Jan; 15(1):261-6. PubMed ID: 19149852
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Prophylaxis in patients with haemophilia complicated by inhibitors].
    Paweł Ł
    Pol Merkur Lekarski; 2011 Mar; 30(177):211-4. PubMed ID: 21545000
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Massive factor-VIII infusion in Haemophiliac with factor-VIII inhibitor, high responder. 1977.
    Brackmann HH; Gormsen J
    Haemophilia; 2010 May; 16(102):2-3. PubMed ID: 20536980
    [No Abstract]   [Full Text] [Related]  

  • 56. Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States.
    Witmer C; Presley R; Kulkarni R; Soucie JM; Manno CS; Raffini L
    Br J Haematol; 2011 Jan; 152(2):211-6. PubMed ID: 21114482
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-world resource use and costs of haemophilia A-related bleeding.
    Shrestha A; Eldar-Lissai A; Hou N; Lakdawalla DN; Batt K
    Haemophilia; 2017 Jul; 23(4):e267-e275. PubMed ID: 28574162
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prophylaxis in haemophilia.
    Lancet; 1971 Jan; 1(7690):118-9. PubMed ID: 4099608
    [No Abstract]   [Full Text] [Related]  

  • 59. Impact of treatment regimen with moroctocog alfa (AF-CC) on bleeding rates in paediatric patients with severe haemophilia A.
    Smith MP; Rupon J; Wali Y; Rimawi H; Korth-Bradley J; Smith L; Rendo P
    Haemophilia; 2020 Sep; 26(5):e232-e235. PubMed ID: 32497363
    [No Abstract]   [Full Text] [Related]  

  • 60. Considerations in individualizing prophylaxis in patients with haemophilia A.
    Valentino LA
    Haemophilia; 2014 Sep; 20(5):607-15. PubMed ID: 24712891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.